FST and acute myeloid leukemia: Moreover, in patients with relapsed or refractory FLT3/ITD AML treated with quizartinib monotherapy, serum FST levels were significantly decreased in four patients upon morphological clearance of marrow blasts at CRi (complete remission with incomplete hematological recovery) but resurged during relapse (Fig 7M).